Tauriga Sciences, Inc. engages in the development, distribution, and licensing of proprietary products. It also engages in evaluation of potential acquisition opportunities and equity investments. The firm focuses on biotherapeutics and diagnostics, medical devices, and consumer healthcare. Its products include Tauri-GUM which contains cannabidoil. The company was founded on April 8, 2001 and is headquartered in New York, NY.
Company profile
Ticker
TAUG
Exchange
Website
CEO
Seth M. Shaw
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ATLANTIC WINE AGENCIES INC, ATLANTICWINE AGENCIES INC, Immunovative, Inc., NEW ENGLAND ACQUISITIONS INC, Novo Energies Corp
SEC CIK
Corporate docs
IRS number
651102237
TAUG stock data
Latest filings (excl ownership)
NT 10-Q
Notice of late quarterly filing
16 Aug 22
NT 10-K/A
Notice of late annual filing (amended)
14 Jul 22
NT 10-K
Notice of late annual filing
30 Jun 22
10-Q
2022 Q3
Quarterly report
16 Feb 22
NT 10-Q
Notice of late quarterly filing
15 Feb 22
8-K
Submission of Matters to a Vote of Security Holders
23 Nov 21
10-Q
2022 Q2
Quarterly report
15 Nov 21
DEF 14A
Definitive proxy
12 Oct 21
PRE 14A
Preliminary proxy
30 Sep 21
8-K
Departure of Directors or Certain Officers
22 Sep 21
Latest ownership filings
4
SETH M SHAW
27 May 21
3
James V Rosati
20 Apr 21
3
Chris Sferruzzo
14 Apr 21
SC 13G
GS Capital Partners, LLC
28 Dec 20
4
SETH M SHAW
10 Jul 20
SC 13D/A
Tauriga Sciences, Inc.
13 Oct 17
4
SETH M SHAW
6 Oct 17
3
Kevin Patrick Lacey
13 Jul 17
SC 13D
Tauriga Sciences, Inc.
26 Jun 17
4
SETH M SHAW
22 Jun 17
Financial summary
Quarter (USD) | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 21 | Mar 20 | Mar 19 | Mar 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.80 k | 6.80 k | 6.80 k | 6.80 k | 6.80 k | 6.80 k |
Cash burn (monthly) | 7.30 k | 13.82 k | 514.09 k | 522.22 k | 87.50 k | 222.75 k |
Cash used (since last report) | 201.77 k | 382.05 k | 14.21 mm | 14.43 mm | 2.42 mm | 6.16 mm |
Cash remaining | -194.98 k | -375.25 k | -14.20 mm | -14.43 mm | -2.41 mm | -6.15 mm |
Runway (months of cash) | -26.7 | -27.1 | -27.6 | -27.6 | -27.6 | -27.6 |
Institutional ownership, Q3 2023
8.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.39 bn |
Total shares | 21.70 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
GS Capital Partners | 21.65 mm | $1.21 mm |
Sofos Investments | 50.69 k | $1.39 bn |